Genentech’s Tecentriq meets PFS endpoint in first-line NSCLC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said Tecentriq atezolizumab met the co-primary endpoint of improving progression-free survival in the Phase III IMpower150 trial as first-line treatment of advanced stage IV

Read the full 326 word article

User Sign In